Literature DB >> 35568275

Acute effects of ketamine and esketamine on cognition in healthy subjects: A meta-analysis.

Simon Zhornitsky1, Valérie Tourjman2, Julie Pelletier3, Roxane Assaf2, Chiang-Shan R Li4, Stéphane Potvin5.   

Abstract

BACKGROUND: Impairment in cognition is frequently associated with acute ketamine administration. However, some questions remain unanswered as to which deficits are most prominent and what variables modulate these effects.
METHODS: A literature search yielded 56 experimental studies of acute ketamine administration that assessed cognition in 1041 healthy volunteers. A multivariate meta-analysis was performed, and effect sizes were estimated for eleven cognitive domains: attention, executive function, response inhibition, social cognition, speed of processing, verbal / language, verbal learning, verbal memory, visual learning & memory, visuospatial abilities, and working memory.
RESULTS: There were small-to-moderate impairments across all cognitive domains. Deficits in verbal learning / memory were most prominent, whereas response inhibition was the least affected. Meta-regression analysis revealed that the negative effects of ketamine on cognition are dependent on infusion dose and plasma level, but unaffected by enantiomer type, route of administration, sex or age. A publication bias was observed. DISCUSSION: Acute ketamine broadly impairs cognition across all domains among healthy individuals. Verbal learning and memory figures most prominently in cognitive impairment elicited by acute ketamine administration.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute administration; Cognition; Ketamine; meta-analysis

Mesh:

Substances:

Year:  2022        PMID: 35568275     DOI: 10.1016/j.pnpbp.2022.110575

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  1 in total

1.  Esketamine prevents propofol-induced injection pain: Randomized controlled trial.

Authors:  Chaozhi Xu; Xiaotang Wei; Cuiwen Zhang; Xiaofang Huang; Hongmeng Lan; Yanping Xu; Xiaoyan Wu; Fuping Li; Xuehai Guan
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.